Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

By Riccardo Lencioni, H. Allgaier, D. Cioni, M. Olschewski, P. Deibert, L. Crocetti, H. Frings, J. Laubenberger, I. Zuber, H. Blum and 1 more. Radiology, 2003

1,013 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/046325e521e3409673bed559c38908560831a16a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Jordi Bruix1 , 2
2. J. Llovet
3. M. Sherman
4. V. Mazzaferro
5. Andrew X. Zhu
6. Peter R. Galle
7. Riccardo Lencioni
8. Alejandro Forner1 , 2

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. M. Sherman
4. Riccardo Lencioni
5. V. Mazzaferro
6. Alejandro Forner1 , 2
7. Andrew X. Zhu
8. Peter R. Galle

Citations in the corpus

• Management of hepatocellular carcinoma (2005, background): “However, there is no evidence that this results in better survival [16].”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “In one analysis including 13 studies (9 small RCT) there was a significant improvement in recurrence-free survival with interferon (estimated 3-year RFS of 54% versus 30% of placebo) [200].”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “In one analysis including 13 studies (9 small RCT) there was a significant improvement in recurrence-free survival with interferon (estimated 3-year RFS of 54% versus 30% of placebo) [200].”
• Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “Conversely, no differences in survival were reported in the European RCT [97] (2-yr survival rates of 98% for RF vs. 88% for PEI, ns).”
• Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects (2010, background): “However, when the nodule size exceeds 3 cm the likelihood for complete response and the absence of recurrence within or surrounding the treated nodule is significantly reduced.(39,65,78) The decrease of efficacy with nodule size is well known with ethanol injection because tumor septa may prevent ad”
• Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, background): “RFA is superior to ethanol injection in the treatment of small HCCs in terms of treatment response, recurrence, and overall survival [294–297], while some investigators reported that RFA had higher complication rates [295, 297].”